A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial) (EPHESUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02608645

Recruitment Status : Unknown

Verified November 2015 by Murat Biteker, Muğla Sıtkı Koçman University.
Recruitment status was: Not yet recruiting

First Posted : November 20, 2015

Last Update Posted : November 20, 2015

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Murat Biteker, Muğla Sıtkı Koçman University

Study Description

Brief Summary:

In this study, within the secondary prevention group patients ( diabetes mellitus, coronary artery disease, peripheral artery disease, who have had events atherosclerotic cerebrovascular ) , statin use requirement , patients compliance and reaching target LDL-cholesterol levels (according to European guidelines ) will be evaluated.

Condition or disease
Hyperlipidemias

Detailed Description:

In the majority of patients treated with lipid lowering agents are not under control in accordance with the lipids manual. In this study, within the secondary prevention group patients ( diabetes mellitus, coronary artery disease, peripheral artery disease, who have had events atherosclerotic cerebrovascular ) , statin use requirement , patients compliance and reaching target LDL-cholesterol levels (according to European guidelines ) will be evaluated.

The investigators' aim is to determine the role of education and knowledge in reaching target LDL cholesterol levels in these patients. İn addition , the investigators want to emphasize in high-risk patients who are receiving or not receiving cholesterol-lowering treatment what is their target values , (LDL < 100 mg / dL and high -risk patients with LDL < 70 mg / dL in very high-risk patients ) and to determine what is the rate of patients and to the importance of reaching their target cholesterol levels. İn addition ,to evaluate the patients habits of the using statin dose .After screening , physician treatment decisions and reasons will be documented.

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	6000 participants
Time Perspective:	Prospective
Official Title:	Evaluation of Perceptions, Knowledge and Compliance With tHE Guidelines for Secondary Prevention in Real Life Practice: A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial)
Study Start Date :	November 2015
Estimated Primary Completion Date :	September 2016
Estimated Study Completion Date :	September 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cholesterol Cholesterol Levels: What You Need to Know

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

The number of patients with secondary prevention group receiving appropriate lipid lowering therapy [ Time Frame: 2 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients receiving lipid-lowering therapy within the secondary prevention group in Turkey

Criteria

Inclusion Criteria:

Patients with coronary artery disease (acute coronary syndromes, post- myocardial infarction patients, who have a history of percutaneous coronary intervention , history of coronary artery by-pass graft )
Patients with carotid artery lesions or peripheral artery disease ,
Type 2 diabetes mellitus patients

Exclusion Criteria:

acute coronary syndrome in last 1 month
pregnancy or the first 6 months postpartum
ICU patients or emergency patients...etc.(other than polyclinic)

Contacts and Locations

No Contacts or Locations Provided

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Dogan V, Basaran O, Ozlek B, Celik O, Ozlek E, Cil C, Ozdemir IH, Rencuzogullari I, Ozpamuk Karadeniz F, Bekar L, Aktas M, Resulzade MM, Kalcik M, Aksan G, Cinier G, Halli Akay K, Mert KU, Biteker M, Kayikcioglu M. Evaluation of perceptions, knowledge and compliance with guidelines in real-life practice: A survey on the under-treatment of hypercholesterolemia. Turk Kardiyol Dern Ars. 2019 Oct;47(7):599-608. doi: 10.5543/tkda.2019.39293.

Dogan V, Basaran O, Ozlek B, Celik O, Ozlek E, Mert KU, Rencuzogullari I, Mert GO, Dogan MM, Biteker M, Kayikcioglu M. Rationale, design, and methodology of the Evaluation of Perceptions, Knowledge, and Compliance with the Guidelines in Real Life Practice: A Survey on the Under-treatment of Hypercholesterolemia. Turk Kardiyol Dern Ars. 2018 Jan;46(1):47-53. doi: 10.5543/tkda.2017.73861.

Layout table for additonal information

Responsible Party:	Murat Biteker, Assoc. Prof. Mugla Sitki Kocman University, Muğla Sıtkı Koçman University
ClinicalTrials.gov Identifier:	NCT02608645
Other Study ID Numbers:	EPHESUS trial
First Posted:	November 20, 2015 Key Record Dates
Last Update Posted:	November 20, 2015
Last Verified:	November 2015

Additional relevant MeSH terms:

Layout table for MeSH terms

Hypercholesterolemia Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases

To Top